+45 45 42 33 93 info@stobbe.com

POC of CellCore – Period: oct-dec 2011

Under Glycomics and Atlantis projects the CellCore™ technology for perfusion cultivation of mammalian cell was developed. Proof-Off-Concept was though missing. The Animal Cell Technology group, Bioprocess / Bioproduction Division, School of Biotechnology, KTH and the Swedish company Belach found resources 2011 from Sweden Innovation Agency for the PoC.

CellTank 2202_02         PoC_KTH_2011

CAD drawing of CellTank and the lab setup at KTH 2011.

The activities of the KTH group are focused on mammalian cell-based processes representative of biopharmaceuticals and stem cell bioprocessing. Several projects of perfusion at high cell density and fed-batch development have been performed since 2008 by the Animal Cell Technology group, Bioprocess/Bioproduction Division, School of Biotechnology, KTH. The group leader, Dr. Veronique Chotteau, as well as PhD Mrs. Ye Zang has an extensive experience in mammalian cell cultivation and industrial biopharmaceutical processes.

Poster_ESACT_KTH_2012        CCE-XIII-conference-poster-20120416
The results was presented at several conferences in US 2012-2014 and posters can be found on www.perfusecell.com/download – thumbnails is shown.


Project was sponsored by Vinnova, Sweden with 0.5 mio SEK – www.vinnova.se/en

PoC II of CellCore – Period: April 2015

Bollinger 2015 - 2           Bollinger 2015 - 1


A follow up project for an article was performed 2015 by PhD Mrs. Ye Zang at KTH.

Article Title
Study of perfusion process of CHO cells with bench-top Single-Use-Bioreactors (SUB) with 150 cm3 CellCore matrix.

Background and novelty
A new perfusion integrated Single-Use-Bioreactor (SUB) culture system CellTank™ has been developed for highly efficient production of recombinant products from mammalian cell lines. In this system, both adherent and suspension mammalian cell lines are harboured in a novel matrix concept (CellCore) composed of two parallel stacked matrix discs caged each in envelopes and immersed in media in a reservoir surrounding the matrix. CellTank™ are scalable by altering the matrix disc diameter and the number of matrix discs, generating a working volume spanning >1:1.000 from few cm3 to 15.000 cm3.

Experimental approach
In this study, suspensionadapted recombinant Chinese Hamster Ovary (CHO) cells producing IgG monoclonal antibody were cultivated in the CellTank 2202 prototype, bench-top SUB with 150 cm3 CellCore matrix. A real-time biomass sensor from FOGALE nanotech using the dielectric properties of living cells was used to measure the live cell density. The operation and performance of this setting were studied in perfusion cultivations.

Results and discussion
A viable cell density of 200 x 106 cells/mL was achieved at perfusion rate 10 RV/day (Reactor Volume per day) during the first run. For the biomass sensor it was found that 1 pF/cm were equivalent to 1 x 106 viable cells/mL. In the second run, viable constant cell at density of 130 x 106 pF/cm was maintained for 11 days at perfusion rate 8 RV/day-10RV/day at reduced temperature. The cell specific productivity was comparable or higher than the one measured in batch culture in Erlenmeyer flasks. The volumetric IgG productivity was up to 61 times higher than in Erlenmeyer flasks batch cultures. There was no retention of IgG in the CellCore matrix.

As a bench-top Single-Use-Bioreactor, the CellTank™ system integrating the cell separation device can work long-term and stably at cell density above 100 x 106 viable cells/mL without IgG retention in the matrix. Being easy and handy to operate, CellTank™ offers a solution alleviating technical and sterility challenges occurring in traditional perfusion processes and makes an excellent choice for bio-therapeutics production.

Keywords: perfusion process, Single-Use-Bioreactor, on-line biomass sensor, dielectric spectroscopy, CHO cells, expression, anti-bodies.


Project was sponsored by the partners.